B
Bull
Bull · 25%TAK
$18.07
Szenariopreis
$17.980
-0.050 (-0.28%)Zum Schluss
Loading chart…
- High
- 18.060
- Open
- 17.990
- VWAP
- 18.00
- Vol
- 1.78M
- Mkt Cap
- 40.51B
- Low
- 17.955
- Amount
- 32.03M
- EV/EBITDA, TTM
- 3.05
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
AI analysis of Takeda Pharmaceutical Co Ltd (TAK)
buyTakeda Pharmaceutical Co Ltd (TAK) is a good buy right now due to its current price of 18.03, which is below the analyst price target of approximately 46.25 USD (converted from 6,900 yen). Additionally, the forward P/E ratio of 11.236 suggests that the stock is reasonably valued compared to its earnings potential. The recent approval of Takeda's ORZEYFUL for narcolepsy treatment is a significant positive catalyst that could enhance future revenue streams. However, investors should be cautious of the net income fluctuations, particularly the recent loss of 368.47 billion JPY in Q4 2026, which indicates volatility in profitability.
Bewertungskennzahlen
The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK) is 11.12, compared to its 5-year average forward P/E of 25.61.
Alphio AI Price Scenarios for TAK
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.508-31FoolJohnson & Johnson's Investment Portfolio Reveals Biotech Potential
9.008-28NewsfilterFDA Approves MIMRYLO for Erythrocytosis Treatment in PV Patients
8.508-28stocktwitsNovavax Vaccine Nuvaxovid Receives Approval for Updated Formulation
- 8.508-24Newsfilter
Takeda's ORZEYFUL Approved for Narcolepsy Treatment
2.008-08NASDAQ.COMTakeda (TAK) Q1 2026 Earnings Call Transcript
TAK FAQ — answered by Alphio AI
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies. It operates in the Healthcare sector.
Takeda Pharmaceutical Co Ltd (TAK) is a good buy right now due to its current price of 18.03, which is below the analyst price target of approximately 46.25 USD (converted from 6,900 yen). Additionally, the forward P/E ratio of 11.236 suggests that the stock is reasonably valued compared to its earnings potential. The recent approval of Takeda's ORZEYFUL for narcolepsy treatment is a significant positive catalyst that could enhance future revenue streams. However, investors should be cautious of the net income fluctuations, particularly the recent loss of 368.47 billion JPY in Q4 2026, which indicates volatility in profitability.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.